← ANALYST RATINGS · TIPRANKS
Alamar Biosciences, Inc. (ALMR): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $32.67, the highest $35.00, the lowest $31.00. The average is +29.2% from the last price of $25.28.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $28.00 → $32.00+14.3% | Buy | +26.6% | Reiterated | 11.08.26on TipRanks 07:30 | +31.0%next day −9.7% · 5 days −9.5% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $30.00 → $31.00+3.3% | Hold | +22.6% | Reiterated | 10.08.26on TipRanks Aug 11 08:50 | −1.6%next day +31.0% · 5 days +14.8% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $32.00 → $35.00+9.4% | Buy | +38.4% | Reiterated | 10.08.26on TipRanks Aug 11 07:35 | −1.6%next day +31.0% · 5 days +14.8% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $30.00 → $34.00+13.3% | Buy | +34.5% | Reiterated | 15.07.26on TipRanks 08:50 | −3.8%next day −4.0% · 5 days −2.9% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $35.00 | Buy | +38.4% | Initiated | 12.05.26on TipRanks 07:50 | −3.7%next day −0.4% · 5 days −10.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Alamar Biosciences, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $33.00 at a price of $34.07 (−3.1%); now: $32.67 at $25.28 (+29.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 3 | 4 | 6 | 5 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.26 to $-0.15). Last quarter: $-0.22.
Sales
Next quarter’s sales estimate — $30M (from $30M to $30M). Last quarter: $29M.
Best top-analyst consensus in the sector · General
About Alamar Biosciences, Inc.
- CEO: Yuling Luo
- Employees: 222
- 47071 Bayside Parkway, Fremont, CA, 94538, US
- www.alamarbio.com
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Data from the stock’s TipRanks forecast page, read 115 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗